Navigation Links
Researchers Discover New Molecular Path to Fight Autoimmune Diseases

Multiple sclerosis, diabetes, and arthritis are among a variety of autoimmune diseases that are aggravated when one type of white blood cell, called the immune regulatory// cell, malfunctions. In humans, one cause of this malfunction is when a mutation in the FOXP3 gene disables the immune cells’ ability to function. In a new study published online this week in the Proceedings of the National Academy of Sciences, researchers at the University of Pennsylvania School of Medicine have discovered how to modify enzymes that act on the FOXP3 protein, in turn making the regulatory immune cells work better. These findings have important implications for treating autoimmune-related diseases.

“We have uncovered a mechanism by which drugs could be developed to stabilize immune regulatory cells in order to fight autoimmune diseases,” says senior author Mark Greene, MD, PhD, the John Eckman Professor of Pathology and Laboratory Medicine. “There’s been little understanding about how the FOXP3 protein actually works.” First author Bin Li, PhD, a research associate in the Greene lab has been working on elucidating this process since FOXP3’s discovery almost five years ago.

Li discovered that the FOXP3 protein works via a complex set of enzymes. One set of those enzymes are called histone deacetylases, or HDACs. These enzymes are linked to the FOXP3 protein in association with another set of enzymes called histone acetyl transferases that modify the FOXP3 proteins.

Li found that when the histone acetyl transferases are turned on, or when the histone deacetylases are turned off, the immune regulatory cells work better and longer. As a consequence of the action of the acetylating enzyme, the FOXP3 protein functions to turn off pathways that would lead to autoimmune diseases.

“I think this simple approach will revolutionize the treatment of autoimmune diseases in humans because we have a new set of enzymatic drug targets as opposed to t he non-specific therapies we now use,” says Greene. Non-specific therapies include the use of steroids and certain chemotherapy-like drugs that act on many cell types and have significant side effects.

“Before this work, FOXP3 was thought essential for regulatory T-cell function, but how FOXP3 worked was not known,” says Li. “Our research identifies a critical mechanism. Based on this mechanism, treatments could be developed to modulate this regulatory cell population.”

“In this line of investigation, we have learned how to turn on or off this regulatory immune cell population – which is normally needed to prevent autoimmune diseases – using drugs that are approved for other purposes, but work on these enzymes” notes co-author Sandra Saouaf, PhD, a research associate at Penn.

Source-Nwswise
SRM
'"/>




Related medicine news :

1. Researchers urge caution in using ear tube surgery
2. Researchers Scale to assess the Severity of Epilepsy in Kids
3. Researchers trick Alzheimers Enzyme
4. Researchers find new HIV hiding place
5. New Hair in 15 Days Could Now Be A Possibility Say Researchers
6. Researchers developed world’s smallest toothbrus
7. Researchers discover receptor cells that can cause epilepsy
8. 15 Anti-SARS Drugs Identified By China-Europe Team of Researchers
9. Researchers reversed the process of memory loss
10. Researchers Identify Key Gene That May Help Brain Treatment
11. Researchers Discover Protein That Causes Malaria
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2016)... , ... April 28, 2016 , ... ... among the organization’s most successful events, attracting medical professionals from around the globe ... stimulating networking events. , Opening Ceremonies Sunday, April 17 included the introduction of ...
(Date:4/28/2016)... Maine (PRWEB) , ... April 28, 2016 , ... In ... death and principal determinant of childhood mortality. This is particularly true in underdeveloped parts ... lecture at the University of New England’s campus in Tangier, Morocco, will examine this ...
(Date:4/28/2016)... NY (PRWEB) , ... April 28, 2016 , ... ... Ingredient of the Year at VitaFoods 2016. , Nominated in the Healthy Ageing ... merit, efficacy, innovation, and safety. The Healthy Ageing division can include everything from ...
(Date:4/28/2016)... AZ (PRWEB) , ... April 28, 2016 , ... ... world leader in Aesthetic Surgery Education and Anzu®, developers of the AnzuMedical™ ... a Nationwide Plastic Surgery Collaborative Residency Network. The platform is scheduled to launch ...
(Date:4/28/2016)... ... April 28, 2016 , ... April, 28, 2016 ... Doc in Physical Medicine and Rehabilitation by Philadelphia Magazine. , Philadelphia Magazine’s annual ... randomly surveying physicians and medical leadership across the country. These select individuals nominate ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 2016 New market research ... a report that provides an overview of the ... by identifying new targets and MOAs to produce ... discussed in this H1 2016 Osteoarthritis Pipeline report ... Inc., Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, ...
(Date:4/27/2016)... Italy , April 27, 2016 ... linear accelerator (MR-linac) platform will be the focal point ... meeting of the European Society for Radiotherapy & Oncology, ... Elekta,s MR-linac integrates a state-of-the-art radiotherapy system and a ... physician to clearly see the patient,s anatomy in real ...
(Date:4/27/2016)... 27, 2016 Shire plc (LSE: SHP, ... , Chief Financial Officer, will present at the Deutsche Bank ... on Wednesday, May 04, 2016, 10:00 am EDT ... available on the Presentations and Webcasts section of Shire,s Investor ... webcast will be available on this same website for approximately ...
Breaking Medicine Technology: